SAGA Diagnostics enters supply agreement with the German Institute for Hematopathology Hamburg

LUND, Sweden – /June 4, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and ultrasensitive monitoring of cancer patients, today announces it has entered a supply agreement with the German Institute for Hematopathology Hamburg, a large private pathology based in Hamburg, Germany.

 

As part of the agreement, the Institute for Hematopathology Hamburg (HpH) will test the SAGAsafe® technology using a range of different clinically relevant mutation assays for potential incorporation into their routine processes. Additionally, HpH will support SAGA in the development of new assays.  

 

HpH is a leading pathology laboratory with more than 220 employees performing a full range of diagnostic services, including advanced molecular diagnostics for leukemia, lymphoma and solid tumors, as well as benign hematologic and lymphatic disorders. Samples from over 80,000 patients are tested yearly. 

 

We are excited to have a large and experienced institute such as the Institute for Hematopathology Hamburg as a partner at our side in Germany to help us getting a better insight into the German market. The collaboration is an important step for our European marketing strategy, and we hope that this way we will soon be able to make the benefits of SAGAsafe® available to patients in Germany through the Institute for Hematopathology Hamburg.

– Annina Hube, SAGA Diagnostics Director of Market Access

 

SAGAsafe® is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance to a limit of detection of ~0.001% mutant allele frequency.  

SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® for monitoring residual cancer disease, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as custom-tailored solutions to fit customers’ needs.  SAGA’s molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms that may help direct therapy.

 


Contact: CEO Lao Saal, MD PhD.   media@sagadiagnostics.com   Phone: +46 (0) 733 01 7242

 

About SAGA Diagnostics AB

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

Follow us on Twitter @SAGAdiagnostics and LinkedIn.